Shandong Xinhua Pharmaceutical Company Limited

SEHK:719 Stok Raporu

Piyasa değeri: HK$10.3b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shandong Xinhua Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Shandong Xinhua Pharmaceutical yıllık ortalama 12.1% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 5.7% annual. Gelirler growing yılda ortalama 9.5% oranında artmaktadır. Shandong Xinhua Pharmaceutical'in özkaynak karlılığı 10.1% ve net marjı 6%'dir.

Anahtar bilgiler

12.1%

Kazanç büyüme oranı

9.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.6%
Gelir büyüme oranı9.5%
Özkaynak getirisi10.1%
Net Marj6.0%
Sonraki Kazanç Güncellemesi30 Oct 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27
These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04
Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09
Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21
We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06
Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19
What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26
Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05
Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29
Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14
Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Gelir ve Gider Dağılımı

Shandong Xinhua Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SEHK:719 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 248,1614921,155427
31 Mar 247,9364871,189449
31 Dec 238,1014971,298419
30 Sep 238,5475101,354428
30 Jun 238,5114861,347413
31 Mar 238,3114541,325379
01 Jan 237,5034111,111346
30 Sep 227,073357980352
30 Jun 226,673343900340
31 Mar 226,623357908343
31 Dec 216,560349931341
30 Sep 216,307364935338
30 Jun 216,271353992311
31 Mar 216,068339957301
31 Dec 206,006325944298
30 Sep 205,814305982261
30 Jun 205,769323990260
31 Mar 205,6823101,049253
31 Dec 195,6063001,105235
30 Sep 195,7163031,107229
30 Jun 195,6802811,072233
31 Mar 195,4572641,012201
31 Dec 185,245255924187
30 Sep 185,023229859172
30 Jun 184,800226809151
31 Mar 184,638226710204
31 Dec 174,516210725161
30 Sep 174,491207718130
30 Jun 174,42018376297
31 Mar 174,3061547990
31 Dec 164,0151227240
30 Sep 163,8001106670
30 Jun 163,6471036240
31 Mar 163,602896110
31 Dec 153,597836110
30 Sep 153,604646130
30 Jun 153,678365930
31 Mar 153,653626040
31 Dec 143,590515650
30 Sep 143,769526140
30 Jun 143,635745890
31 Mar 143,588505440
31 Dec 133,391395010

Kaliteli Kazançlar: 719 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 719 'nin mevcut net kar marjları (6%) geçen yılın (5.7%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 719 şirketinin kazancı son 5 yılda yılda 12.1% oranında arttı.

Büyüme Hızlandırma: 719 'un son bir yıldaki kazanç büyümesi ( 1.2% ) 5 yıllık ortalamasının ( 12.1% /yıl) altındadır.

Kazançlar vs. Sektör: 719 geçen yılki kazanç büyümesi ( 1.2% ) Pharmaceuticals sektörünün 6.4% performansını geride bırakmadı.


Özkaynak Getirisi

Yüksek ROE: 719 'nin Özsermaye Getirisi ( 10.1% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin